Suitability of superficial electron paramagnetic resonance dosimetry for in vivo measurement and verification of cumulative total doses during IMRT: A proof of principle. by Höfel, Sebastian et al.
ARTICLE IN PRESSZEMEDI-10881; No. of Pages 13
ORIGINAL PAPER
Suitability of superficial electron paramagnetic resonance
dosimetry  for in vivo measurement and verification of
cumulative total doses during IMRT: A proof of principle
Sebastian Höfela,b,∗, Michael K. Fixc, Malte Dreschera, Felix Zwickerb,d,e
a Department of Chemistry and Konstanz Research School Chemical Biology, University of Konstanz, Germany
b Klinik und Praxis für Strahlentherapie am Klinikum Konstanz, Konstanz, Germany
c Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and
University  of Bern, Switzerland
d Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
e Clinical Cooperation Unit Molecular Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Received 24 November 2020; accepted 31 March 2021
Abstract
Purpose:  The  present  study  investigates  superficial  in  vivo  dosimetry  (IVD)  by  means  of  a previously  proposed  electron
paramagnetic resonance  (EPR)  dosimetry  system  aiming  at  measuring  and  verifying  total  doses  delivered  by  complex
radiotherapy treatments.  In  view  of  novel  regulatory  requirements  in  Germany,  differences  between  measured  and  planned
total doses  to  the  EPR  dosimeters  are  analyzed  and  compared  to  reporting  thresholds  for  significant  occurrences.
Methods: EPR  dosimeters,  each  consisting  of  one  lithium  formate  monohydrate  (LFM)  and  one  polycrystalline  l-alanine
(ALA) pellet,  were  attached  to  the  surface  of  an  anthropomorphic  head  phantom.  Three  head  and  neck  treatments  with  total
target doses  ranging  from  30  to  64  Gy  were  fully  delivered  to  the  phantom  by  helical  tomotherapy.  During  each  treatment,
eight EPR  dosimeters  were  placed  at  distinct  spots:  (i)  within  or  next  to  the  planning  target  volume  (PTV),  (ii)  near  to
organs at  risk  including  the  parotid  glands  and  the  eye  lenses,  (iii)  at  the  thyroid  lying  out-of-field.  EPR  read  out  was
always performed  after  all  fractions  were  delivered.  EPR  results  were  compared  to  thermoluminescence  dosimeter  (TLD)
measurements and  to the  planned  total  doses  derived  from  the  treatment  planning  system  (TPS).  Planned  total  doses  to  the
EPR dosimeters  ranged  from  about  2  to  64  Gy.
Results:  By  taking  uncertainties  into  account,  the  measured  and  planned  doses  were  in  good  agreement.  Exceptions
occurred mainly  at  the  thyroid  (out-of-field)  and  lenses  (extreme  sparing).  The  maximum  total  dose  difference  between  EPR
results and  corresponding  planned  doses  was  1.3  Gy  occurring  at  the  lenses.  Remarkably,  each  LFM  and  ALA  pellet  placed
within or  next  to  the  PTV  provided  dose  values  that  were  within  ±4%  of  the  planned  dose.  Dose  deviations  from  planned
dose values  were  comparable  for  EPR  and  TLD  measurements.
Conclusion: The  results  of  this  proof  of  principle  study  suggest  that  superficial  EPR-IVD  is  applicable  in  a  wide  dose  range
and in various  irradiation  conditions  – being  a valuable  tool  for  monitoring  cumulative  total  doses  delivered  by  complex
IMRT treatments.  EPR-IVD  in  combination  with  helical  tomotherapy  is  suitable  to  reliably  detect  local  dose  deviations  at
superficial dosimeter  spots  in  the  order  of  current  national  reporting  thresholds  for  significant  occurrences  (i.e.  10%/4  Gy).Keywords: In vivo, EPR dosimetry, Lithium formate, Alanine
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1 Introduction
In vivo dosimetry (IVD) aims to determine actually deliv-
ered radiation doses to patients undergoing radiotherapy
treatments. IVD is a well-recognized and valuable method
being used for different purposes. Primarily, it is applied
for ultimate quality assurance in radiotherapy since it allows
verification of radiation doses to organs at risk (OAR) and
target structures during treatments by comparing measured
versus planned doses. By this means and according to inter-
national guidelines, IVD complements pretreatment quality
checks and verifications by providing an additional and inde-
pendent safeguard for the detection of errors in the treatment
chain [1]. Moreover, IVD can be used in regions lying outside
the treatment beams (out-of-field) - even beyond the imaging
dataset used for treatment planning, i.e. where no dose values
are predicted by the treatment planning system (TPS). The
latter situations play an important role e.g. when estimating
fetal doses or the risk of secondary cancer induction [2] in the
context of radioprotection.
International organizations have been promoting clinical
implementation of IVD in radiotherapy [1,3–5], and devel-
oped procedures for several point detectors [6,7]. Despite its
huge potential for error detection, quality assurance, and accu-
racy improvements in radiotherapy, however, IVD is not yet
mandatory in many countries.
Since recently, the importance of correct dose delivery
in radiotherapy is reflected in Germany’s national regula-
tory requirements: In the course of the transposition of the
council directive 2013/59/EURATOM [8] into national law, a
new radiation protection act [9] and radiation protection ordi-
nance [10] came into force. In this context, a central reporting
system for significant occurrences in the medical field has
been established on the national level. Significant occurrences
include severe deviations of the total delivered dose from
the planned dose for both, target volumes and OARs. Dose
deviation by more than 10% or 4 Gy are defined as reporting
thresholds [10]. Compliance with these regulations requires
new efforts and ideas considering the technical realization of
monitoring delivered doses in clinical routine. It is expected
that these new requirements will strengthen the reasoning in
favor of IVD, since it is the only way of reliably determin-
ing and documenting actually delivered radiation doses to
patients.
So far only little attention was paid to using electron para-
magnetic resonance (EPR) dosimetry as an IVD technique –
presumably due to the high efforts associated with precise EPR
dosimetry protocols based on alanine (ALA). EPR dosimetry
offers many advantages for clinical application such as dose
response linearity, water equivalence and independence of the
detector response regarding beam quality and dose rate [11].
In vivo applications of EPR dosimetry using ALA were first
reported during total body irradiations [12,13], and shortly
thereafter also in brachytherapy [14,15]. More recently, ALA
dosimetry was performed in body cavities during prostate [16]ys xxx (2021) xxx–xxx
and gynecological [17] external beam radiotherapy (EBRT).
Lately, also superficial in vivo application of ALA dosimeters
at the contralateral breast during volumetric modulated arc
therapy (VMAT) of breast cancer patients was shown [18].
In a previous study [19], we reported on uncertainties of
EPR dosimetry using lithium formate monohydrate (LFM)
as EPR sensitive material in the radiotherapy dose range by
applying a practical dosimetry protocol tailored for routine
clinical use in radiotherapy. For LFM, the uncertainties (1σ)
were below 3% in the entire dose range between 1 and 70 Gy.
The aim of the current study is to demonstrate the appli-
cability of the proposed EPR dosimetry system as an IVD
tool being capable of measuring superficial radiation doses
delivered during an entire course of a complex intensity mod-
ulated radiotherapy (IMRT) treatment. In order to assess the
applicability of LFM dosimeters for future routine IVD during
EBRT, the resulting dose values are compared to ALA dosime-
try results, to TLD measurements and to the planned dose
values based on TPS calculations. Moreover, an uncertainty
analysis of measured and planned superficial dose values is
performed to assess the reliability of superficial dose verifi-
cation – especially in view of current reporting thresholds in
Germany applying to total dose deviations in radiotherapy.
2 Materials and methods
For illustration purposes, some figures in this chapter were
generated by using EclipseTM radiotherapy treatment plan-
ning software version 15.6.6 (Varian, Palo Alto, CA, USA).
2.1  EPR  and  TLD  dosimeter  design
Each EPR dosimeter consisted of a cylindrical polypropy-
lene capsule with an outer diameter of 6.4 mm and a length
of 12 mm containing two different EPR sensitive pellets: one
ALA and one LFM pellet as shown in Figure 1(a). The EPR
sensitive pellets had a cylindrical shape with a diameter of
4 mm and a height of 2 mm (ALA) or 4 mm (LFM). Synthetic
rubber plugs (black part in Figure 1(a)) were used to fix the
pellets positions inside the capsule and to close the capsules
at the end. Further details regarding dosimeter preparation are
provided in [19].
Lithium fluoride (LiF) TLD detectors (TLD-100) were
received from PTW Freiburg GmbH (Freiburg i. Br., Ger-
many). Each TLD detector consisted of a cylindrical TLD
chip (diameter of 4 mm, height of 1 mm) that was encapsu-
lated in a cylindrical polymethyl methacrylate (PMMA) rod
with a length of 2.5 cm and a diameter of 5 mm. All TLD chips
were exactly located in the center of the PMMA rods.
2.2  Phantom,  dosimeter  placement  and  CTThe dosimeters were placed at distinct positions (here-
inafter referred to as spots) located on the surface of an
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Figure 1. Cross-sections parallel to the EPR dosimeters’ symmetry axis. Sketch and dimensions of EPR dosimeter design (a). Exemplary
coronal view of an EPR dosimeter’s representation in the planning CT image and the two most appropriate contouring versions cv#1 (b)
and cv#2 (c) for the ALA and LFM pellets. ALA and LFM contours are shown in cyan and dark blue colors, respectively.
Table 1
Summary and comparison of the investigated irradiation scenarios.
Irradiation scenarios Labels SC#1 SC#2 SC#3
Treatment case WBRT WBRT OROPH
Prescribed dose 30 Gy in 10 fractions 30 Gy in 10 fractions 64 Gy in 32 fractions (SIB)
57.6 Gy in 32 fractions (PTV)
Normalization D50(PTV) = 30 Gy D50(PTV) = 30 Gy D50(PTV) = 57.6 Gy
OARs Parotid glands, eyes, eye lenses,
mandibular joints, thyroid
Parotid glands, eyes, eye
lenses, mandibular joints,
thyroid













Chin (5 mm bolus)







Next to right parotid gland
Next to left parotid gland
Next to right eye lens
Next to left eye lens
(complete beam blocking)
Next to right thyroid lobe (about 2–3 cm from caudal field edge)
Next to left thyroid lobe (about 2–3 cm from caudal field edge)
Total treatment time
period
1 h 1.5 h 6 weeks
Positioning of EPR
dosimeters




 lasPositioning of phantom Once initially according to
markings
anthropomorphic head phantom (Alderson phantom, RSD
Phantoms, CA, USA): either within or next to target structures
or close to OARs.
Three different irradiation scenarios (SC#1-3) are inves-
tigated (cf. Table 1 and Section 2.4). For each scenario,
eight dosimeter spots were defined and labeled as illustrated
in Figure 2. The labels reflect the associated anatomical
structures: lenses (Le), parotid glands (Pa), target (Ta) and
thyroid (Th). As seen in Figure 2, the third letter indicates
the left(L)/right(R) side of the phantom. The dosimeter spots
for scenarios SC#1 and SC#2 were the same. In scenarios
SC#1/SC#2, TaL is located between the phantoms left fore-
head and a 5 mm bolus, while in scenario SC#3 the targeter Once initially according
to laser markings
Repositioned in between
fractions according to laser
markings
dosimeters TaR and TaL are located underneath a 5 mm bolus
at the phantom’s chin.
All dosimeter spots were marked with velcro strips on the
phantom’s body. Corresponding velcro stickers were attached
to the EPR as well as the TLD dosimeters in order to place
them within a maximum isotropic deviation of ±2 mm from
the indented position.
For both detector types, great care was taken that the
dosimeters’ symmetry axis was always in parallel with the
y-direction according to the International Electrotechnical
Commission (IEC) accelerator coordinate system.
Computed tomography (CT) datasets were acquired for
treatment planning using a SOMATOM® Definition Flash
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Figure 2. Superficial dosimeter placements (green spots) on the phantom’s body (brown surface) for irradiation scenarios SC#1/SC#2 (top)
), p
pos
and SC#3 (bottom). Dosimeter labels shown in green (target (TaR/TaL
and bolus material in translucent yellow. Definition of the phantom 
(Siemens Healthcare, Erlangen, Germany) CT scanner. Image
reconstruction was performed by applying filtered back pro-
jection with a conventional kernel (B31s) and 2 mm slice
width. In total, four CT scans of the phantom were performed:
Two for each dosimeter setup shown in Figure 2 (SC#1/SC#2
or SC#3) with either eight EPR or eight TLD dosimeters
attached. The two CT datasets showing the EPR dosimeters
were used as primary CTs during treatment planning whereas
the CT datasets with TLDs served for dose re-calculation (cf.
Section 2.5).
2.3  Treatment  planning
For either dosimeter setup shown in Figure 2, a com-
plex head and neck treatment plan was created using helical
Tomotherapy (Accuray Inc., Sunnyvale, CA, USA).
The first treatment plan (WBRT) was created for irradia-
tions scenarios SC#1 and SC#2 and simulates a whole-brain
radiotherapy including subcutaneous and bone metastases.
The inferior field border was extended to the sixth cervi-
cal vertebra of the spine. The planning target volume (PTV)arotid glands (PaR/PaL), eye lenses (LeR/LeL), thyroid (ThR/ThL))
ition in relation to the IEC coordinate system.
included a fictitious subcutaneous metastasis at the left fore-
head – where the 5 mm bolus and target dosimeter TaL was
applied (Figure 2). A helical tomotherapy plan was created
with the following settings: Longitudinal field width of 5 cm
(dynamic jaw mode), pitch of 0.297 and planning modulation
factor of 2.0. A total median dose of 30 Gy in 10 fractions
(3.0 Gy single fraction dose) was prescribed to the PTV. Plan
normalization was set accordingly to D50(PTV) = 30 Gy.
The second treatment plan was created for irradiation sce-
nario SC#3 following a clinical case of a ventral floor of mouth
cancer (OROPH) with infiltration of the ventral mandible and
lips. A helical tomotherapy plan was created with the fol-
lowing settings: Longitudinal field width of 5 cm (dynamic
jaw mode), pitch of 0.297 and planning modulation fac-
tor of 2.4. A total median dose of 57.6 Gy in 32 fractions
(1.8 Gy single fraction dose) was prescribed to the PTV which
extended from the base of the skull to the hyoid bone in cranio-
caudal direction. Plan normalization was set accordingly to
D50(PTV) = 57.6 Gy. The PTV completely encompassed the
oropharynx and the lymph node levels I and II. A simulta-
neous integrated boost (SIB) was defined in the oral cavity
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as a sub-volume of the PTV. The SIB volume was extended
ventrally to include the lips, parts of the 5 mm bolus material
and two EPR dosimeters. The planned median dose in the SIB
volume was 63.9 Gy.
For both treatment plans, the following OARs located in-
field were contoured and considered during optimization:
eyes, eye lenses, parotid glands and mandibular joints. The
thyroid was contoured as well, but was located inferior to
the caudal field border (out-of-field). In the OROPH case, the
spinal cord was considered as OAR additionally.
Note that the exact structure of the eyes, eye lenses, parotid
glands and the thyroid were not identifiable in the phantom’s
CT. Therefore, OAR contouring was rather based on experi-
ence than on visible structures.
In both cases, the thyroid dosimeter spots were located out-
of-field, i.e. about 2–3 cm from the inferior edge of the PTV.
The mean doses to the eye lenses and the respective dosime-
ter spots were pushed below 6 Gy during optimization of both
plans. Additionally, the left lens and dosimeter LeL were
completely blocked by the collimator system, i.e. no primary
photon fluence passed through these regions. Corresponding
binary leafs of the multileaf collimator (MLC) were automat-
ically closed.
Dose calculation was performed using Accuray’s Precision
2.0.1.1 (Accuray Inc., Sunnyvale, CA, USA) TPS. Both, the
CT voxel matrix and the calculation grid had an axial spatial
resolution of 1 mm (IEC x–z-plane). In IEC y-direction, the
dose grid had a spatial resolution of 2 mm corresponding to
the CT slice thickness.
2.4  Irradiation  scenarios
Phantom irradiations were performed using a clinical
Tomotherapy Hi-Art® treatment machine (Accuray Inc., Sun-
nyvale, CA, USA). The tomotherapy machine is calibrated
against the TPS following the concept of plan-class specific
reference fields [20,21]. The same ionization chamber was
used for calibration of machine output and calibration of the
EPR dosimetry system [19].
Three different irradiation scenarios were applied to the
EPR dosimeters. A summary and comparison is given in
Table 1.
Irradiation scenarios SC#1 and SC#2 were conducted by
applying all fractions of treatment plan WBRT. In scenario
SC#1, the EPR dosimeters were not repositioned in between
fractions, but were left exactly at the same location in relation
to the phantom surface as during acquisition of the planning
CT. Before the first fraction, the phantom was positioned on
the treatment couch according to superficial markings for the
in-room laser system as defined in the treatment plan. The
phantom stayed in this initial position during the delivery of
all fractions.
SC#2 was conducted right after SC#1. The only differ-
ence between SC#1 and SC#2 was that the EPR dosimeterss xxx (2021) xxx–xxx 5
were removed and straightaway re-attached to the respective
dosimeter spot between fractions.
Irradiation scenario SC#3 mimicked a realistic fractionated
head and neck treatment extending over a treatment period of
more than 6 weeks (32 fractions) and including repositioning
of the dosimeters as well as repositioning of the phantom
in between fractions. Before each fraction, the phantom was
positioned on the treatment couch as planned according to
superficial markings for the in-room laser system.
In contrary to clinical practice, no daily image guidance via
megavoltage CT (MVCT) was performed, since correct posi-
tioning of the rigid phantom was considered to be reproducible
within an isotropic tolerance of ±1 mm by means of the laser
system and, moreover, the imaging dose is not considered in
the total dose calculation of the TPS.
All EPR dosimeters were irradiated at room temperature
(20–25 ◦C). Before and after irradiation, the EPR dosimeters
were stored in an air-tight box that provided a constant level
of 34 ±  2% relative humidity.
For an independent dosimetry check, TLD detectors were
used to measure single fraction doses to the dosimeter spots.
TLD irradiations were performed for both treatment plans. A
minimum of three fractions were delivered, each to a different
set of TLD detectors.
2.5  Planned  dose  determination
Planned doses to the EPR pellets were derived from TPS
calculations as follows. For each EPR dosimeter, ALA and
LFM pellets were contoured separately with a diameter of
4 mm on the primary CT. Due to the finite CT slice thick-
ness (2 mm) and the resulting partial volume artefacts, two
contouring versions (cv#1 and cv#2) were chosen to cap-
ture the pellets’ true position. An example is shown in
Figure 1(b) and (c). Each pellet i was thus represented by
two structures (Svc#1i ,  S
vc#2
i ). After final dose calculation,
mean dose values Dm within the pellet structures for both
contouring versions (Dm(Svc#1i ),  Dm(S
vc#2
i )) were extracted
from the dose statistics table of the TPS. For each pellet, the
planned dose Dp was defined as the mean value of the mean
doses calculated within the two associated structures (Dp =
mean{Dm(Svc#1i ),  Dm(Svc#2i )}). The absolute half of the dif-
ference between the two mean dose values (1/2|Dm(Svc#1i ) −
Dm(Svc#2i )|) was taken as uncertainty component for contour-
ing (cf. Section 2.7).
An equivalent procedure was performed for the TLD chips
using the secondary CT dataset. After contouring, the sec-
ondary CT was registered to the primary CT. The treatment
plan was then applied to the secondary CT, i.e. the dose
distribution was re-calculated. Planned dose values were
determined as described above.2.6  Dose  measurements
EPR measurements were performed on a compact benchtop
spectrometer (MiniScope MS 5000, Magnettech by Freiberg
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Instruments GmbH, Freiberg, Germany) immediately after
all fractions were delivered. Each pellet was measured for
10 min. A detailed description of the measuring and evalu-
ation procedure is presented in a previous study [19]. Since
the EPR dosimeters were irradiated at room temperature (as
the dosimeters used for calibration) no additional temperature
correction was applied.
For the EPR dosimeters irradiated over a period of about 6
weeks (SC#3), fading correction was considered. In order to
account for fading, it was assumed that the EPR dosimeters
were irradiated at a specific date lying in the middle between
the first and the last day of treatment. For the ALA pellets, a
fading correction factor of 1.0026 was calculated and applied
(fading rate is about 3% per year). Regarding the LFM dosime-
ters, fading affects not only the signal amplitude but also the
line shape of the EPR spectrum. A fading correction was
inherently considered during spectral evaluation by choosing
the appropriate LFM base spectrum (week 5) from the set of
available base spectra [19].
Absorbed dose values at the dosimeter spots were also
obtained via TLD irradiations (Section 2.4). The irradiated
TLDs were immediately evaluated by PTW Freiburg GmbH
taking beam quality correction (6 MV) into account. For each
dosimeter spot, the results of minimum three irradiated TLDs
were averaged. Unlike in the case of the EPR measurements,
the TLD mean values reflect the dose delivered during one
single fraction. For direct comparison with the planned total
dose values and the EPR results, the TLD mean values were
multiplied by the respective number of total fractions.
The irradiation conditions investigated in this work (dose
build-up region, complex helical IMRT plan) are considerably
different from typical reference conditions and the conditions
applied for the calibration of the EPR dosimeters (10 cm depth,
fixed beam, etc.) [19]. Hence, the dose response of ALA-
EPR, LFM-EPR and LiF-TLD detectors might change when
applied on the surface or in shallow depths (e.g. underneath
5 mm bolus). In order to assess possible changes in the detec-
tor response, Monte Carlo (MC) simulations were performed
using the Geant4 [22] toolkit and a validated phase-space file
for the tomotherapy beam [23,24]. In the simulation geome-
try, EPR and TLD dosimeters as defined in Section 2.1 were
placed next to the surface of a water phantom. The dosimeters’
responses at the surface (DDosimeter/DH2O)Surface (for vari-
ous angles of beam incidence) in relation to the dosimeters’
responses under reference conditions (DDosimeter/DH2O)Ref
were investigated. For each dosimeter material, the ratios
(DDosimeter/DH2O)Surface/(DDosimeter/DH2O)Ref were averaged
over all beam incidence angles resulting in surface correc-
tion factors kSurface for complex irradiation scenarios. The
surface correction factors including standard uncertainties
were kSurface,ALA = 0.991(5) for ALA, kSurface,LFM = 0.990(7)
for LFM and kSurface,LiF = 0.996(27) for LiF. Although rel-
ative corrections were determined to be very small (<1%),
the surface correction factors were applied to the respec-
tive measurement results. Moreover, an additional uncertaintyys xxx (2021) xxx–xxx
contribution due to surface application was taken into account
(cf. Table 2 and Section 2.7).
2.7  Uncertainty  considerations
Uncertainties in this work are determined and expressed in
accordance with the Guide to the Expression of Uncertainty
in Measurement published by the International Organization
for Standardization [25]. Unless otherwise stated, all uncer-
tainties are to be seen as type B standard uncertainties (1σ),
i.e. the stated standard uncertainties are based on previous
measurements, scientific judgement or experience.
Uncertainty budgets for the planned dose and the measured
doses values (EPR and TLD) are summarized in Table 2.
For the planned dose (cf. Section 2.5), the following
uncertainty components were considered: (i) estimated dose
uncertainty of 0.5% emerging from the uncertainty of the CT’s
hounsfield units (HU), (ii) uncertainty of the beam model
beyond the dose build-up region (0.5%), i.e. mean deviation
between measured and modeled depth dose curves and beam
profiles. Based on the tomotherapy out-of-field dose accuracy
study of Schneider et al. [26], an increased uncertainty of
5% was attributed to locations receiving a small fraction of
the prescribed dose (2–30% of the prescribed dose), i.e. the
dosimeter spots lying out-of-field (ThL and ThR) or in regions
where primary beam incidence was considerably suppressed
due to OAR sparing (PaL, PaR, LeL, LeR), (iii) additional
uncertainty of tomotherapy’s convolution/superposition dose
calculation algorithm in the build-up region (2.0% assumed),
(iv) output fluctuations of the treatment machine (based on
daily ionization chamber measurements). For the target spots
TaL and TaR, the combined uncertainty of the TPS was esti-
mated to be 2.2% (5.4% for the other dosimeter spots lying
predominantly out of the primary beam).
An additional uncertainty due to contouring of the dosime-
ter pellets as described in Section 2.5 was taken into account.
The determination of relative measurement uncertainties
for the EPR method was described in a previous study [19].
Due to less controlled conditions during superficial in vivo
applications, an additional uncertainty contribution of 0.2%
regarding temperature effects is taken into account in the cur-
rent study. In addition, uncertainties of the fading correction
procedure were estimated to 0.1% (ALA) and 0.3% (LFM).
For dose measurements in the build-up region, an extra uncer-
tainty component of the surface correction factor had to be
taken into account (cf. Section 2.6).
The dose accuracy of the TLD results were stated by PTW
as 1.5% for single fraction doses above 150 mGy and 2.5% for
doses below 150 mGy. As for EPR, an additional uncertainty
contribution needs to be considered when TLDs are applied
in the dose build-up region. Based on MC simulations, this
uncertainty contribution is considerably higher for LiF-TLD
(2.7%) compared to EPR (0.5% ALA, 0.7% LFM).
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Table 2
Uncertainty budgets for calculation based planned dose values and measured dose values given as relative standard uncertainties (1σ).
Uncertainty budgets
Planned dose Dose measured by EPR
ALA LFM
Component Rel. standard uncertainty
[%]




HU uncertainty 0.5 Fading 0.1 0.3
Beam model basic data
(out of primary beam)
0.5 (5.0) Irradiation temperature 0.2 0.2
Dose calculation in
build-up
2.0 Application in dose
build-up
0.5 0.7
Output fluctuations of the
treatment machine
0.5 EPR measurement result






TPS dose (out of primary
beam)
2.2 (5.4) Total combined
uncertainty for EPR at
2/5/10/ 6.5/2.7/1.4/ 1.9/1.2/1.0/
20/30/60 Gy 0.9/0.7/0.7 0.9/0.9/0.9
Additional contributions:
Contouring of the pellets Specific to each pellet
(see text)
Dose measured by TLD
LiF
Ranges (min. . . . max.)
for the total combined
uncertainty of the planned
dose
ALA: (2.2 . . . 22.0) Component Rel. stand. uncertainty [%]
LFM: (2.2 . . . 18.2) Dose corrected for 6 MV
beam as stated by PTW
2.5 (below 150 mGy/fraction)
1.5 (above 150 mGy/fraction)




 for cf. Table 4 Total comb
uncertainty
The total combined uncertainties given in Table 2 were
obtained by calculating the square-root of the sum of the single
squared uncertainty contributions.
Planned doses (Dp, Section 2.5) and measured doses (Dm,
Section 2.6) obtained in this work are estimations of the
actually delivered doses to the dosimeters. The planned dose
neglects the uncertainty of repositioning of the dosimeters in
relation to the phantom surface (SC#2, SC#3) and position-
ing of the phantom in relation to the treatment beam (for all
scenarios).
The combined uncertainty uc(D) of the
dose difference D  = Dm −  Dp is calculated via
uc(D)2 = uc(Dp)2 + uc(Dm)2.
3 ResultsFigure 3 shows the locations of the superficial dosimeter
spots in relation to the planned dose distributions of the applied
head and neck irradiation scenarios (SC#1-3) described inTLD
3.7 (below 150 mGy/fraction)
3.1 (above 150 mGy/fraction)
Table 1. Total planned doses to the contoured OARs are given
in Table 3.
As can be seen in Figure 3, the dosimeters were placed
in different irradiation situations: Within or next to the PTV
(TaL,TaR), next to OARs located in-field (eye lenses: LeL,
LeR; parotid glands: PaL, PaR) or out-of-field (thyroid: ThL,
ThR).
Planned (Dp) and measured (Dm) total dose values in com-
bination with absolute standard uncertainties (Section 2.7)
for all dosimeter spots and irradiation scenarios are listed
in Table 4. Agreement between measured and planned dose
values can be assessed from the overlapping of uncertainty
margins (1σ). According to this criterion, agreement between
measured and planned doses is observed for both, EPR and
TLD dosimeters at the target (TaR and TaL), thyroid (ThR
and ThL) and parotid (PaR and PaL) spots. Some exceptions
occurred which are underlined in Table 4. Note that none of
the measured dose values at the eye lenses (LeL and LeR)
were in agreement with the planned dose.
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Figure 3. Axial views of the calculated dose distribution superimposed on the corresponding primary CT slices illustrating the dosimeters’
locations for the irradiation scenarios SC#1/SC#2 (top) and SC#3 (bottom). Dosimeter spots and corresponding labels are shown in green.
Contours of target structures (PTV (orange), SIB (black)) and OARs (le
(white)) are displayed. The thyroid was located outside the primary bea
Table 3
Planned total doses to OARs: Eyes, eye lenses, mandibular joints
(MJ), parotid glands (PG), thyroid and spinal cord.
Irradiation scenarios SC#1/SC#2 SC#3
Treatment WBRT OROPH
Mean OAR dose [Gy]
Eye L 10.6 2.2
Eye R 12.0 10.7
Lens L 2.5 1.7
Lens R 3.9 5.8
MJ L 25.8 36.9
MJ R 26.8 35.2
PG L 12.2 24.9
PG R 11.9 25.0
Thyroid 3.4 2.0
lens spots (LeR and LeL). At these locations, the uncertaintySpinal cord – 33.6 (Max)
Differences between measured and planned dose values at
each dosimeter spot and for each dosimetry technique (ALA-
EPR, LFM-EPR and LiF-TLD) are illustrated in Figure 4.
The dose differences Dm −  Dp are shown in absolute as well
as relative terms with respect to the planned dose. Uncertainty
margins for the dose difference (Section 2.7) are indicated by
the error bars.nses (yellow), parotid glands (pink), spinal cord (cyan) and thyroid
m (out-of-field).
Looking at all EPR measurements, absolute dose differ-
ences Dm −  Dp were always below 1.3 Gy (observed with
ALA for spot LeR in irradiation scenario SC#2).
With regard to using EPR dosimetry for treatment veri-
fication, the dose differences and the associated combined
uncertainties at the target spots are of special interest. At
these spots, the maximum absolute dose difference Dm −  Dp
was 1.15 Gy (SC#3, TaL) for ALA and 0.88 Gy for LFM
(TaR, SC#2). In relative terms, the dose differences were
1.8% (ALA, TaL, SC#3) and 4.0% (LFM, TaR, SC#2). Except
for TaR in SC#2, the error bars in Figure 4 cover the zero-
difference line, i.e. the observed dose differences at the target
spots were mostly within uncertainties (1σ).
At the parotid spots (PaL and PaR), the TPS systemati-
cally underestimated the dose by about 0.25 Gy (SC#1/SC#2)
and 0.5 Gy (SC#3). However, the observed dose underesti-
mation was still within uncertainty margins. Expressed in
relative terms, this dose underestimation is approximately
4% (SC#1/SC#2) or 2.5% (SC#3) of the planned dose at the
parotid spots and about 0.8% of the respective prescribed dose.
More reliable dose differences Dm −  Dp are observed at themargins (1σ) for measured and planned doses did not overlap
(cf. Table 4). As for the parotid spots, an underestimation of
the TPS dose was observed (cf. Figure 4). It amounts up to
ARTICLE IN PRESS
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Table 4
Comparison of planned doses Dp versus measured doses Dm for each irradiation scenario and dosimeter spot. Respective combined uncer-
tainties uc are given in brackets as absolute standard uncertainties (1σ). Underlined numbers mark observations for which the uncertainty
margins of planned and measured values do not overlap.
Spot ALA-EPR LFM-EPR LiF-TLD












































TaL 64.54(1.42) 65.69(0.44) 64.51(1.42) 64.20(0.59) 65.02(1.43) 66.54(2.06)
TaR 64.53(1.42) 63.50(0.43) 64.51(1.42) 64.21(0.59) 64.59(1.42) 64.32(1.99)
PaL 19.33(1.12) 19.64(0.18) 19.56(1.06) 20.17(0.19) 20.25(1.10) 20.69(0.64)
PaR 20.13(1.13) 21.04(0.19) 19.22(1.12) 19.92(0.19) 20.49(1.13) 21.68(0.67)
LeL 1.58(0.09) 2.37(0.13) 1.51(0.08) 2.17(0.04) 1.64(0.09) 2.09(0.08)
4.
3.
2.LeR 4.93(0.28) 6.03(0.14) 
ThL 2.12(0.13) 2.32(0.13) 
ThR 3.64(0.57) 3.90(0.13) 
1.3 Gy for LeR in SC#2. In relation to the prescribed dose, the
dose differences observed at the lens spots were in the order
of 4% or below. With respect to the planned dose at the lens
spots, however, the relative dose difference is considerable (up
to 50%, e.g. LeL in SC#3).
No clear systematic dose under- or overestimation was
observed for the thyroid spots. Relative combined uncertain-
ties for the dose difference were highest for the thyroid spots,
since the thyroid dosimeters were located out-of-field (about
2–3 cm from the inferior field border, i.e. still within con-
siderable relative dose gradients in IEC y-direction) and the
gradient strength in y-direction is reflected in the contouring
uncertainty contribution (Section 2.5). Although considerable
relative deviations from the planned dose were observed (e.g.
28% for LFM at ThL in SC#1), the differences were still within
uncertainties in most cases.
Three main observations result from Figure 4. Firstly, the
observed absolute dose differences between EPR measure-
ments and the planned dose are small (<1.3 Gy) and combined
m puncertainties (1σ) for the dose difference D −  D were
always below 1.6 Gy. Secondly, by taking uncertainty mar-
gins into account, the dose differences Dm −  Dp observed for
LFM and ALA at each dosimeter spot are consistent with63(0.27) 5.33(0.07) 4.94(0.32) 5.47(0.17)
08(0.40) 3.11(0.05) 2.15(0.16) 2.19(0.08)
42(0.20) 2.65(0.05) 2.22(0.16) 2.21(0.08)
each other. Similarly, the dose differences observed with EPR
dosimetry are in agreement with the respective TLD results.
One exception occurred at spot LeL in SC#3. Thirdly, the EPR
measurements of both pellet types as well as the TLD mea-
surements at the lens spots were significantly higher than the
respective planned dose suggesting some limitations of the
TPS dose calculation algorithm for these irradiation condi-
tions. Good agreement, however, is found for the target spots
– within ±4% of the planned dose.
4 Discussion
Different irradiation scenarios (Table 1 and Figure 3) with
total doses to the dosimeters ranging from about 2 to 64 Gy
were investigated and a detailed uncertainty analysis for the
measured and planned dose values was performed (Table 2
and Table 4 and Figure 4).
By taking uncertainty margins into account, the differences
between measured and planned doses at each dosimeter spot
were comparable for EPR and TLD dosimetry. Evaluation of
the TLDs was performed externally by the German secondary
standard dosimetry laboratory at PTW Freiburg GmbH. TLD
dose values were considered as ground truth and served as
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Figure 4. Absolute (left) and relative (right) local dose differences between measured and planned total dose values for irradiation scenarios
SC#1 (top), SC#2 (middle) and SC#3 (bottom). For comparison, results of ALA-EPR (blue stars), LFM-EPR (purple triangles) and LiF-
 un
es.TLD (green circles) are grouped for each dosimeter spot. Combined
Reporting thresholds (10%/4 Gy) are indicated by red horizontal lin
an independent check for the EPR-IVD procedure. Based on
the TLD comparison, the applied EPR-IVD procedure has
proven to be reliable and suitable. During the analysis, mate-
rial dependent surface correction factors with corresponding
uncertainties resulting from MC simulations were considered
(Section 2.6). Relative corrections for superficial application
were small (<1%) in relation to the established uncertain-
ties (see Table 4 and Figure 4). Due to the good agreement
observed between the measured values at each dosimeter spot
(Figure 4), these correction values are supported by the exper-
imental results of this work. Further support is found in thecertainties (1σ) of the dose difference are represented by error bars.
literature. A previously reported value of the surface cor-
rection factor for ALA is kQ,in-vivo = 0.988(10) [18], which
is in good agreement with the correction factor presented
in this work. Besides, it was shown experimentally that the
dependence of the EPR response on dose rate [27,28], and
beam quality [29,30], is of minor importance for therapeutic
beams.
All phantom irradiations were successfully performed as
specified by the applied treatment plans. The planned total
doses at the dosimeter spots derived from TPS calculations
should ideally match the actually delivered dose at these
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locations, especially in scenario SC#1 where the dosimeters’
positions during irradiation exactly matched the planned sit-
uation. For SC#2 and SC#3, deviations were expected, since
the dosimeters were repositioned between fractions. In SC#3,
not only the dosimeters but also the phantom was repositioned
between fractions mimicking a realistic head and neck treat-
ment. Concerning verification of planned doses by superficial
IVD measurements, two questions arise: (i) How large are the
differences between measured and planned total doses at the
dosimeter spots for ideal (SC#1) and more complex (SC#2,
SC#3) treatment scenarios, (ii) are the determined differences
still within uncertainty margins and how large are the uncer-
tainty margins compared to the desired accuracy level. The
underlying primary question is, however, whether the dose cal-
culation algorithm of the TPS fulfills high levels of accuracy
at the superficial dosimeter spots (dose build-up region).
By taking uncertainties into account, agreement between
measured and planned dose values was found for all target
dosimeters placed underneath a 5 mm bolus (TaR and TaL in
SC#3, TaL in SC#1 and SC#2). Agreement was also found for
the EPR results at spot TaR (no bolus) in SC#1. In SC#2, the
EPR dosimeters were repositioned between fractions leading
to an increased dose difference at spot TaR. The results demon-
strate that a relative combined uncertainty of only 2.2% for
tomotherapy’s dose calculation in the build-up region is justi-
fiable and that the agreement between measured and planned
target doses is more robust, when 5 mm bolus is applied.
Apart from the target spots, agreement between measured
and planned dose values was observed for the parotid spots
in all scenarios, even though a small overall dose difference
was observed. These results show the feasibility of superficial
total dose verification by EPR-IVD next to OARs without the
use of additional bolus.
As can be seen in Figure 4, the dose differences and the
corresponding uncertainties for the target and parotid spots
are smaller than current reporting thresholds for significant
occurrences [10]: For target volumes, deviations of ±10%
from the planned mean dose has to be reported. Also local
dose deviations of ±10% with respect to the planned dose
within target structures are subject to mandatory reporting
as long as the absolute value of the dose difference exceeds
4 Gy. For OARs, reporting thresholds relating to mean OAR
doses lie 10% above the respective planned mean dose or 10%
above the dose constraint defined in the institution’s standard
operating procedures. The red horizontal lines in Figure 4
indicate reporting thresholds when these criteria are trans-
lated to the planned dose values at the dosimeter spots. The
EPR measurements at the target and parotid spots showed a
maximum deviation of 4% and 1.15 Gy with respect to the
planned dose. The uncertainties (1σ) for the dose difference
did not exceed 1.54 Gy and 6% in absolute and relative terms,
respectively. The observed dose differences and correspond-
ing uncertainties for EPR-IVD are small compared to the
(10%/4 Gy) criterion. Dose deviations to superficial dosime-
ter spots by more than 10%/4 Gy can thus be reliably detected. xxx (2021) xxx–xxx 11
Superficial EPR-IVD could be used as an additional safe-
guard monitoring total doses to target as well as superficial
OAR structures (e.g. the parotid glands): Severe dose devia-
tions at the dosimeters spots may prompt further investigations
whether the criteria for reporting are met.
In contrary to previously reported dose overestimation at
shallow depths of up to 13% [31–33] for Tomotherapy’s dose
calculation algorithm in the build-up region, the results of this
work show good agreement between measured and planned
doses within ±4% for the target and parotid spots.
The dosimeter spots representing the eye lenses (LeL and
LeR) were located in-field but direct exposure was suppressed
during treatment planning. As seen in Figure 4, the TPS obvi-
ously underestimated the dose to the lens spots (LeR, LeL) in
all three scenarios. At these spots, EPR measurements were in
good agreement with the TLD results (Table 4 and Figure 4)
and the estimated uncertainty margins for the measured and
planned dose values (cf. Table 4) did not overlap, whereas
no systematic dose under- or overestimation was observed
for the thyroid spots lying out-of-field. Possible explanations
are that Accuray’s convolution/superposition dose calculation
algorithm for tomotherapy neglects electron contamination,
MLC transmission and dose contributions from scattered pho-
tons or secondary particles originating from closed MLC leafs
[34,35]. While such dose contributions are marginal (e.g. leaf
transmission is about 0.3% of the primary radiation [36]) and
can be neglected for target locations receiving high doses and
facing open leafs, this additional radiation may lead to con-
siderable relative dose contributions in regions that are spared
from primary beam incidence – especially when lying near to
the surface. In this work, the relative dose difference was high-
est for the LeL spot in SC#3 which was completely blocked
(cf. Section 2.3). Remarkable dose differences between mea-
sured and planned dose values for OARs during tomotherapy
treatment were already reported by other researchers: Reyn-
ders et al. performed TLD measurements in an Alderson
phantom undergoing a helical tomotherapy breast treatment.
For the TLDs located at OARs away from the PTV (contralat-
eral thorax wall, contralateral lung) receiving doses below
10% of the prescribed dose, the measured doses were con-
siderably underestimated by the TPS while the planned target
doses matched the measured results [37]. Consequently, cau-
tion is advised when using calculated doses for radiation
risk assessments in regions of extreme OAR sparing. Fur-
ther investigations regarding the root cause of the observed
discrepancies were beyond the scope of the present work.
As it can be seen from Table 2 and Table 4 and from the
results shown in Figure 4, the main advantage of using LFM
pellets is related to the relative dose uncertainty. While both,
ALA and LFM have comparable low relative dose uncertain-
ties in the order of 0.7–0.9% (1σ) at high doses (>30 Gy),
a high level of precision can be maintained at lower doses
when using LFM dosimeters (rel. combined uncertainty <2%
(1σ) for doses >2 Gy relative to calibrated ionization chamber
dose measurements). It is a well-known characteristic of EPR
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dosimetry that relative uncertainties increase with decreasing
dose in the therapy dose range [38]. This is due to a constant,
i.e. dose independent, uncertainty contribution that dominates
the relative uncertainty at low doses. For LFM, this contribu-
tion expressed in terms of absolute dose is smaller since EPR
signal intensities are higher compared to ALA. The higher
EPR signal intensities result from intrinsic EPR properties
(smaller spectral width) and the doubled volume of the LFM
pellets. The larger longitudinal extent of the LFM pellets lead
to another advantage for in vivo dosimetry: The determination
of the planned dose (Section 2.5) is more reliable for LFM than
for ALA and TLD, i.e. more robust against contouring errors
or longitudinal misplacements (IEC y-direction). Both bene-
ficial facts are reflected by the decreased uncertainty margins
for LFM (compared to ALA) in Figure 4 at the lens and thyroid
spots (low dose, high relative dose gradients).
The limitation of IVD using point detectors is that the
absorbed dose is determined only at single or few points
and that the dosimeter reading is sensitive to positional vari-
ations – especially in IMRT where steep dose gradients in
the vicinity of the PTV are expected. The IMRT treatments
performed in this work were applied to a rigid phantom geom-
etry. While in scenario SC#1 the dosimeters were irradiated
at the same position as planned, the dosimeters were reposi-
tioned between fractions in scenarios SC#2 and SC#3. During
repositioning, a maximum isotropic positional tolerance of
±2 mm was met. Positional inaccuracies were neglected in
the uncertainty analysis (Table 2). By comparing the dose
differences shown in Figure 4 for SC#1 to the respective val-
ues observed for SC#2, it is seen that repositioning of the
dosimeters within the above mentioned tolerance did not have
a remarkable impact on the result for the dosimeter spots inves-
tigated in this work. However, accurate dosimeter positioning
is a crucial prerequisite for EPR in vivo dose verification as
already shown by Wagner et al. [39] for head and neck cancer
patients.
In this study, a practical EPR dosimetry system was vali-
dated as IVD tool to measure and verify total doses applied in
realistic IMRT scenarios. The EPR dosimetry procedure is tai-
lored for routine use featuring a measurement time of 10 min
per pellet [19]. A rigid anthropomorphic phantom was used in
order to verify the dosimetric procedure against TLD measure-
ments. Patient related uncertainties due to deformable body
surfaces and anatomical changes could thereby be excluded.
Future EPR dosimetry studies may assess the dosimetric
impact of these patient related uncertainties. EPR dosimetry is
considered to be particularly useful for IVD of superficial total
target doses, e.g. when bolus material is applied. Moreover,
IVD at field junctions or pacemakers as well as out-of-field
measurements are promising fields of application. Although
in this study the EPR dosimeters were read out once after
treatment was finished, earlier and repetitive evaluations are
principally possible with EPR dosimetry since the dose read-
out is non-destructive. By this means, dosimetric verification
of ongoing treatments is feasible. Finally, EPR dosimetry mayys xxx (2021) xxx–xxx
provide an independent treatment record confirming that dose
delivery was within expected tolerances.
Clinical implementation of EPR-IVD may be a valuable
tool owing to low fading rates, superficial applicability and
high levels of precision for a wide dose range – especially
when using LFM dosimeters.
5 Conclusion
The present study shows that superficial in vivo EPR
dosimetry is suitable for measuring and verification of total
doses delivered during complex IMRT treatments for all cases
considered.
EPR-IVD in this work was performed with two different
dosimeter materials: Self-pressed LFM and commercial ALA
pellets. Due to their higher robustness regarding contouring
errors and misplacements as well as higher levels of precision
at lower doses, the LFM pellets used in this work are preferable
for IVD compared to commercial ALA pellets.
Relevant differences between measured and planned total
doses in the order of current reporting thresholds for sig-
nificant occurrences (10%/4 Gy) can be reliably detected by
superficial EPR dosimetry and, thus, superficial EPR-IVD
may serve as an additional safeguard during the delivery of
complex IMRT treatments in the future.
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